Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Michiko Tsuneizumi"'
Autor:
Shoko Sato, Sae Imada, Ryosuke Hayami, Kazumori Arai, Rieko Kosugi, Michiko Tsuneizumi, Ryoichi Matsunuma
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 208-216 (2024)
Introduction: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in br
Externí odkaz:
https://doaj.org/article/98b7cfff5b0b4a17899dceb823305312
Autor:
Toko Kumeta, Kei Yamaguchi, Ryosuke Hayami, Kazumori Arai, Michiko Tsuneizumi, Ryoichi Matsunuma
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 544-551 (2023)
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with higher rates of relapse and mortality compared to other subtypes. Chemotherapy has been a mainstream treatment approach for TNBC due to the lack of therape
Externí odkaz:
https://doaj.org/article/ac661745ab9148578cc5616035661f74
Autor:
Ryoichi Matsunuma, Shoko Sato, Jason Yongsheng Chan, Kazuo Kinoshita, Keisei Taku, Kei Yamaguchi, Ryosuke Hayami, Kazumori Arai, Makoto Suzuki, Michiko Tsuneizumi
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 455-464 (2023)
Primary breast angiosarcoma is an extremely rare disease with a poor prognosis. Primary angiosarcoma is distinct from secondary angiosarcoma, which usually occurs in patients who have been previously treated for breast cancer. The low incidence of pr
Externí odkaz:
https://doaj.org/article/01b8dea502f74710824caf4522c58c74
Autor:
Masataka Sawaki, Naruto Taira, Yukari Uemura, Tsuyoshi Saito, Shinichi Baba, Kokoro Kobayashi, Hiroaki Kawashima, Michiko Tsuneizumi, Noriko Sagawa, Hiroko Bando, Masato Takahashi, Miki Yamaguchi, Tsutomu Takashima, Takahiro Nakayama, Masahiro Kashiwaba, Toshiro Mizuno, Yutaka Yamamoto, Hiroji Iwata, Tatsuya Toyama, Koichiro Tsugawa, Takuya Kawahara, Hirofumi Mukai
Publikováno v:
Breast, Vol 66, Iss , Pp 245-254 (2022)
Purpose: To gauge the effects of treatment practices on prognosis for older patients with HER2-positive early breast cancer, particularly to determine whether adjuvant trastuzumab alone can offer benefit over no adjuvant therapy. This is a prospectiv
Externí odkaz:
https://doaj.org/article/a945b7265854493eb752770a4643139b
Autor:
Yuki Usui, Ryoichi Matsunuma, Kei Yamaguchi, Ryosuke Hayami, Aya Muramatsu, Makoto Suzuki, Michiko Tsuneizumi
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1536-1541 (2021)
Squamous cell carcinoma (SCC) of the breast is a rare malignancy that usually has a triple-negative phenotype and poor clinical outcomes. Because HER2-positive SCC of the breast is extremely rare, its clinicopathologic features are understudied, and
Externí odkaz:
https://doaj.org/article/09fd35ec4759494b829fca657c485bbb
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 580-584 (2021)
Advanced breast cancer with skin ulceration, bleeding, and odor is associated with impaired quality of life (QoL). In patients with metastatic breast cancer, treatment aims to relieve symptoms, improve QoL, and slow the progression of cancer. Occasio
Externí odkaz:
https://doaj.org/article/e0cf7a492fcc4094859cc576c6d6dea8
Autor:
Kei Yamaguchi, Ryoichi Matsunuma, Toko Kumeta, Sae Imada, Ryosuke Hayami, Kazumori Arai, Makoto Suzuki, Michiko Tsuneizumi
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 3, Pp 1410-1414 (2020)
Bowen’s disease is a squamous cell carcinoma in situ that commonly develops on the trunk, arms, or legs and has not spread beyond the top layer of skin. It seldom develops on the nipple. We report a patient who presented with Bowen’s disease of t
Externí odkaz:
https://doaj.org/article/b019dbc20de3487fa71acd2fc1e7def2
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 170-175 (2020)
Everolimus, an inhibitor of the rapamycin pathway, is administered with the combination of an aromatase inhibitor for the treatment of metastatic estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast canc
Externí odkaz:
https://doaj.org/article/34cc40bc16de427eacca042821fe751b
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 814-819 (2019)
Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeu
Externí odkaz:
https://doaj.org/article/450fa073a050405cb32efb3204cef811
Publikováno v:
Oncology. 100:155-162
Introduction: Not only the 21-gene recurrence score (RS) assay but also online prognostic tools and immunohistochemical prognostic models predict chemotherapy benefits for women with early breast cancer (BC). Multigene assays, including Oncotype DX,